Market Cap 564.58M
Revenue (ttm) 0.00
Net Income (ttm) -155.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.83
Volume 2,662,400
Avg Vol 3,134,332
Day's Range N/A - N/A
Shares Out 96.02M
Stochastic %K 8%
Beta 1.90
Analysts Strong Sell
Price Target $21.92

Company Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incor...

Industry: Medical Care Facilities
Sector: Healthcare
Address:
33 Broadwick Street, London, United Kingdom
TechnicalGuidanceOffice
TechnicalGuidanceOffice Mar. 20 at 8:44 AM
$CMPS is in biotech, just watching.
0 · Reply
Apes_Strong
Apes_Strong Mar. 19 at 8:25 PM
$CMPS that market cap does not include the recent warrants exercise
1 · Reply
Jormungand
Jormungand Mar. 19 at 7:11 PM
$CMPS actually gap filled like nothing happened. Wow.
0 · Reply
FBP
FBP Mar. 19 at 4:10 PM
$CMPS this is a 1.2b company on pdufa day. Very easy place to enter or add with sub 700mc
1 · Reply
Indialli1309
Indialli1309 Mar. 19 at 2:52 PM
$CMPS https://finance.yahoo.com/sectors/healthcare/articles/compass-pathways-eyes-rolling-fda-082816500.html Pending!
0 · Reply
Apes_Strong
Apes_Strong Mar. 19 at 2:40 PM
$CMPS 💯
1 · Reply
Jaashh
Jaashh Mar. 19 at 1:51 PM
A lot of people missing what’s happening with $CMPS. The Jan financing was ~$4.275 for a share + warrant with a $5.796 strike. If investors exercise the warrants, their blended cost basis is roughly ~$5/share. That means funds from the deal can short stock above ~$5 and hedge it with their warrants. Until that supply is absorbed, every bounce is likely to get sold.
1 · Reply
stoxx0007
stoxx0007 Mar. 19 at 1:37 PM
0 · Reply
FBP
FBP Mar. 19 at 1:35 PM
$CMPS added
0 · Reply
twiggs462
twiggs462 Mar. 19 at 1:30 PM
$DFTX $ATAI $CMPS Ukraine's Other Battle: Healing the Invisible Wounds of War Ukraine's therapists seek ways to fund trials of psychedelics despite huge hurdles. https://www.psychologytoday.com/us/blog/patient-revolution/202603/ukraines-other-battle-healing-the-invisible-wounds-of-war
0 · Reply
Latest News on CMPS
COMPASS Pathways plc (CMPS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 11:16 AM EST - 4 months ago

COMPASS Pathways plc (CMPS) Q3 2025 Earnings Call Transcript


COMPASS Pathways plc (CMPS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 10:32 AM EDT - 8 months ago

COMPASS Pathways plc (CMPS) Q2 2025 Earnings Call Transcript


Compass Pathways Appoints Justin Gover to Board of Directors

Jul 29, 2025, 6:30 AM EDT - 8 months ago

Compass Pathways Appoints Justin Gover to Board of Directors


Compass Pathways' depression drug succeeds late-stage trial

Jun 23, 2025, 6:48 AM EDT - 9 months ago

Compass Pathways' depression drug succeeds late-stage trial


COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:14 AM EDT - 11 months ago

COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript


This Is a Test From GlobeNewswire

Mar 28, 2025, 5:01 PM EDT - 1 year ago

This Is a Test From GlobeNewswire

ALVO


Compass Pathways to Participate in Stifel Virtual CNS Forum

Mar 11, 2025, 6:30 AM EDT - 1 year ago

Compass Pathways to Participate in Stifel Virtual CNS Forum


Compass Pathways: Betting On The Future Of Psilocybin Therapy

Feb 28, 2025, 5:08 PM EST - 1 year ago

Compass Pathways: Betting On The Future Of Psilocybin Therapy


TechnicalGuidanceOffice
TechnicalGuidanceOffice Mar. 20 at 8:44 AM
$CMPS is in biotech, just watching.
0 · Reply
Apes_Strong
Apes_Strong Mar. 19 at 8:25 PM
$CMPS that market cap does not include the recent warrants exercise
1 · Reply
Jormungand
Jormungand Mar. 19 at 7:11 PM
$CMPS actually gap filled like nothing happened. Wow.
0 · Reply
FBP
FBP Mar. 19 at 4:10 PM
$CMPS this is a 1.2b company on pdufa day. Very easy place to enter or add with sub 700mc
1 · Reply
Indialli1309
Indialli1309 Mar. 19 at 2:52 PM
$CMPS https://finance.yahoo.com/sectors/healthcare/articles/compass-pathways-eyes-rolling-fda-082816500.html Pending!
0 · Reply
Apes_Strong
Apes_Strong Mar. 19 at 2:40 PM
$CMPS 💯
1 · Reply
Jaashh
Jaashh Mar. 19 at 1:51 PM
A lot of people missing what’s happening with $CMPS. The Jan financing was ~$4.275 for a share + warrant with a $5.796 strike. If investors exercise the warrants, their blended cost basis is roughly ~$5/share. That means funds from the deal can short stock above ~$5 and hedge it with their warrants. Until that supply is absorbed, every bounce is likely to get sold.
1 · Reply
stoxx0007
stoxx0007 Mar. 19 at 1:37 PM
0 · Reply
FBP
FBP Mar. 19 at 1:35 PM
$CMPS added
0 · Reply
twiggs462
twiggs462 Mar. 19 at 1:30 PM
$DFTX $ATAI $CMPS Ukraine's Other Battle: Healing the Invisible Wounds of War Ukraine's therapists seek ways to fund trials of psychedelics despite huge hurdles. https://www.psychologytoday.com/us/blog/patient-revolution/202603/ukraines-other-battle-healing-the-invisible-wounds-of-war
0 · Reply
Apes_Strong
Apes_Strong Mar. 19 at 12:38 PM
$CMPS this could turn us
0 · Reply
Apes_Strong
Apes_Strong Mar. 19 at 12:37 PM
$CMPS yup
1 · Reply
Indialli1309
Indialli1309 Mar. 19 at 10:43 AM
$CMPS https://www.marketbeat.com/instant-alerts/compass-pathways-eyes-rolling-fda-filing-for-comp360-preps-trd-launch-ahead-of-q3-data-2026-03-19/ Big!
0 · Reply
ClownThePoet
ClownThePoet Mar. 19 at 4:17 AM
$CMPS what a joke. we got rugged
0 · Reply
cacci11
cacci11 Mar. 19 at 3:50 AM
$CMPS here comes the green tide rolling in
0 · Reply
FBP
FBP Mar. 18 at 7:18 PM
$CMPS now 3/26 er? Sorry been busy in overall market sales finally coming
3 · Reply
navle
navle Mar. 18 at 5:51 PM
$CMPS $ATAI $DFTX $HELP In the field of psychedelic medicine, I don't think they're worried about the competition coming from $IXHL
1 · Reply
Jormungand
Jormungand Mar. 18 at 5:18 PM
$CMPS down nearly 30% in one month, almost all red days...fuck me.
0 · Reply
Apes_Strong
Apes_Strong Mar. 18 at 3:26 PM
$ATAI $CMPS $DFTX $HELP anything else from the commentary ? Or Q and a ?
1 · Reply
Apes_Strong
Apes_Strong Mar. 18 at 3:19 PM
$CMPS 6. PTSD optionality adds a second large indication. The Phase 2 open-label PTSD study showed promising signals. Compass’s Phase 2 study showed sustained symptom reduction through 12 weeks after a single 25mg dose, with no serious adverse events — setting up a potential blockbuster second indication in a therapeutic area with essentially no innovation in 25 years. 7. M&A optionality. Wall Street has rumored AbbVie deal interest, signaling momentum for psychedelics M&A. A company with two Phase 3 wins and an imminent NDA submission is a natural acquisition target for large pharma seeking CNS pipeline. 8. TD Cowen and Stifel both bullish post-data. TD Cowen wrote that the firm strongly believes COMP360 will get approved and will have “robust market uptake,” and Stifel noted that COMP360 is “3-for-3” and that many antidepressants have been commercially successful despite multiple failed trials.
0 · Reply
Apes_Strong
Apes_Strong Mar. 18 at 3:19 PM
$CMPS 4. Commercial infrastructure already exists — de-risked delivery model. Launch planning is designed to leverage existing interventional psychiatry infrastructure, with more than 7,000 U.S. sites already supporting multi-hour monitored treatments such as Spravato. The FDA has directed Compass to reference the Spravato REMS as a reference point, suggesting a manageable compliance framework. 5. Political and regulatory tailwinds. FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr. have both voiced support for the development of psychedelic drugs, leading proponents to hope the agency will help get them on the market faster. This is a rare moment of bipartisan enthusiasm for a novel drug class.
0 · Reply
Apes_Strong
Apes_Strong Mar. 18 at 3:18 PM
$CMPS Bull Thesis 1. Unprecedented 3-for-3 clinical consistency across 1,000+ participants. Across three robust, well-designed clinical trials involving more than 1,000 participants, Compass has demonstrated consistent, highly statistically significant results at the primary endpoint — a remarkable achievement in the TRD population where proving benefit has historically been extraordinarily challenging. 2. Transformative efficacy profile — rapid onset, durable response, minimal dosing burden. Unlike SSRIs that require daily pills for months, the 26-week data indicated that a subset of patients maintained clinically meaningful benefit with one or two treatments through at least six months, and among those receiving a second administration, 40% subsequently entered remission. No current antidepressant can offer effect onset the day after a single administration.
0 · Reply